Mathias Rummel

9.0k total citations · 1 hit paper
128 papers, 5.0k citations indexed

About

Mathias Rummel is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Mathias Rummel has authored 128 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pathology and Forensic Medicine, 72 papers in Genetics and 46 papers in Oncology. Recurrent topics in Mathias Rummel's work include Lymphoma Diagnosis and Treatment (85 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Viral-associated cancers and disorders (19 papers). Mathias Rummel is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Viral-associated cancers and disorders (19 papers). Mathias Rummel collaborates with scholars based in Germany, United States and Switzerland. Mathias Rummel's co-authors include Dieter Hoelzer, Bruce D. Cheson, Eckhart Weidmann, Dorothea Kofahl-Krause, Wolfram Brugger, Paris S. Mitrou, Ulrich von Grünhagen, Juergen Barth, Manfred Welslau and Ulrich Kaiser and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mathias Rummel

124 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, Ulrich von Grünhagen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathias Rummel Germany	29	3.1k	2.2k	2.1k	1.6k	692	128	5.0k
Michael Unterhalt Germany	33	4.0k 1.3×	2.0k 0.9×	3.0k 1.5×	636 0.4×	732 1.1×	166	5.0k
Sonali M. Smith United States	40	4.2k 1.3×	2.3k 1.1×	3.3k 1.6×	1.3k 0.8×	547 0.8×	263	6.8k
Angelo Michele Carella Italy	38	2.9k 0.9×	1.6k 0.7×	2.8k 1.4×	3.0k 1.9×	535 0.8×	234	6.3k
Réda Bouabdallah France	28	1.9k 0.6×	913 0.4×	2.0k 1.0×	1.5k 0.9×	347 0.5×	101	4.0k
Morton Coleman United States	47	4.8k 1.5×	3.3k 1.5×	3.0k 1.4×	2.1k 1.3×	1.1k 1.5×	306	8.2k
F Reyes France	30	3.4k 1.1×	1.5k 0.7×	2.3k 1.1×	789 0.5×	442 0.6×	64	4.9k
Ivana N. Micallef United States	45	3.3k 1.1×	1.7k 0.8×	3.2k 1.6×	2.9k 1.8×	411 0.6×	256	7.4k
Aspasia Stamatoullas France	34	1.7k 0.6×	1.2k 0.5×	1.3k 0.6×	1.4k 0.9×	289 0.4×	126	3.6k
Jeffrey Matous United States	29	2.3k 0.7×	1.6k 0.7×	1.8k 0.9×	1.2k 0.8×	286 0.4×	128	4.2k
Ercole Brusamolino Italy	32	1.8k 0.6×	1.4k 0.6×	1.6k 0.8×	995 0.6×	551 0.8×	104	4.1k

Countries citing papers authored by Mathias Rummel

Since Specialization

Citations

This map shows the geographic impact of Mathias Rummel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Rummel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Rummel more than expected).

Fields of papers citing papers by Mathias Rummel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Rummel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Rummel. The network helps show where Mathias Rummel may publish in the future.

Co-authorship network of co-authors of Mathias Rummel

This figure shows the co-authorship network connecting the top 25 collaborators of Mathias Rummel. A scholar is included among the top collaborators of Mathias Rummel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathias Rummel. Mathias Rummel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schubert, Maria‐Luisa, Peter Dreger, Anita Schmitt, et al.. (2024). Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 38(11). 2419–2428. 18 indexed citations

Wulf, Gerald, Ulrike Bacher, Mathias Rummel, et al.. (2024). Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe. Cancer Medicine. 13(10). e7289–e7289. 1 indexed citations

Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2023). Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland. Oncology Research and Treatment. 46(Suppl. 2). 5–44. 13 indexed citations

Zimmermann, Heiner, Christian Koenecke, Martin Dreyling, et al.. (2022). Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. 36(10). 2468–2478. 15 indexed citations

Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2022). Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie. Oncology Research and Treatment. 46(Suppl. 1). 7–56.

Rummel, Mathias, Ann Janssens, David MacDonald, et al.. (2021). A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study). British Journal of Haematology. 193(6). 1123–1133. 8 indexed citations

Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745. 3 indexed citations

Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations

Fenk, Roland, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.. (2020). Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. Clinical Cancer Research. 26(22). 5879–5886. 4 indexed citations

10.

Sohlbach, Kristina, Stephan Metzelder, Ellen Wollmer, et al.. (2019). Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation. Leukemia & lymphoma. 60(8). 2056–2061. 3 indexed citations

11.

Bräuninger, Andreas, Wolfgang Blau, Alexander Brobeil, et al.. (2018). Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines. Journal of Molecular Diagnostics. 20(3). 344–354. 6 indexed citations

12.

Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. 161(3). 411–423. 203 indexed citations

13.

Bacher, Ulrike, Torsten Haferlach, Tamara Alpermann, et al.. (2011). Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. British Journal of Haematology. 152(6). 713–720. 41 indexed citations

14.

Roeb, Elke, Mathias Rummel, Werner J. Blau, Benjamin Etschmann, & Stefan Gattenlöhner. (2011). B-cell lymphoma in a tubular adenoma with high-grade dysplasia: a rare extramedullary manifestation of high-grade diffuse large B-cell lymphoma. Endoscopy. 43(S 02). E344–E345. 3 indexed citations

15.

Engert, Andreas, Volker Diehl, Jeremy Franklin, et al.. (2009). Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. Journal of Clinical Oncology. 27(27). 4548–4554. 303 indexed citations

16.

Rummel, Mathias, S. Al-Batran, Manfred Welslau, et al.. (2005). Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 23(15). 3383–3389. 332 indexed citations

17.

Armitage, Jamés O., Kensei Tobinai, Dieter Hoelzer, & Mathias Rummel. (2004). Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone. International Journal of Hematology. 79(4). 311–321. 12 indexed citations

18.

Rummel, Mathias, Sven de Vos, Dieter Hoelzer, H. Phillip Koeffler, & Wolf‐K. Hofmann. (2003). Altered Apoptosis Pathways in Mantle Cell Lymphoma. Leukemia & lymphoma. 45(1). 49–54. 26 indexed citations

19.

Rummel, Mathias, Kai Uwe Chow, Elke Jäger, et al.. (1999). Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Annals of Oncology. 10(1). 115–118. 19 indexed citations

20.

Rummel, Mathias, Michael Schenk, Alexander Knuth, et al.. (1997). Fludarabine Plus Epirubicin in Untreated or Minimal Pretreated Patients with Chronic Lymphocytic Leukemia – Preliminary Results of a Phase-ll Study. Oncology Research and Treatment. 20(4). 328–331. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact